|
Welcome to iiCON's quarterly newsletter
|
|
Welcome to this edition of our newsletter, which explores iiCON's work supporting industry and policy makers to optimally position health interventions for some of the world's most challenging infectious diseases.
In addition to supporting the discovery and development of new antimicrobial products and treatments, enabling effective deployment is a key area of activity for the consortium. By leveraging world-leading global research expertise, we work closely with industry and policy makers to support the effective placement and positioning of interventions within communities through our Platform 8 workstream. This is vital to ensuring optimum impact once products reach patients or are deployed within key communities.
A busy 18 months since our launch in 2020 has seen the programme continue to have significant impact. From supporting a diverse variety of innovative new antimicrobial treatments and products to market, working to combat vaccine inequity, and leveraging world-leading research in the global battle to better understand and combat antimicrobial resistance (AMR), our programme is effectively enabling industry and academic co-innovation to save lives.
We hope you enjoy this insight into our work. To learn more about our programme, visit: www.infectioninnovation.com
Best wishes,
Professor Janet Hemingway
iiCON founding Director
|
|
iiCON supports 11 products to market in first 18 months
iiCON has supported 11 new products to market since launching in September 2020, with a further 16 in the development pipeline.
|
|
|
Leveraging global learnings to combat Anti-Microbial Resistance
Following The Lancet's publication of the most comprehensive assessment of AMR to date, we explore the importance of collaboration in fighting this ever-evolving global threat.
|
|
|
iiCON launches project to track resistant bacteria within the community
An interdisciplinary study has launched to monitor the key transmission routes of resistant bacteria between care homes, hospitals & the community.
|
|
|
Global insight is helping boost vaccine uptake in Liverpool
An innovative programme leveraging global health learnings & driven by community-led innovation teams has launched with an aim to halve vaccine inequity levels in Liverpool.
|
|
|
iiCON supports Liverpool City Region Innovation Plan Parliament launch
Infection Control is one of three world-leading regional specialisms highlighted within the multi-billion pound Innovation Prospectus which launched in Parliament this month.
|
|
|
Don't miss our upcoming Pitching Masterclass
|
|
|
|
About iiCON: Infection Innovation Consortium
A global collaborative infectious disease R&D programme, iiCON was established in 2020. Founded with government funding provided through UK Research and Innovation’s flagship Strength in Places Fund, it brings together industry, academia, and the NHS in a concerted effort with a clear aim: to combat the growing global threat posed by infectious diseases and save lives through collaborative innovation.
Led by Liverpool School of Tropical Medicine, our consortium partners Unilever, Liverpool University Hospitals Foundation Trust, University of Liverpool, Evotec, and Infex Therapeutics are working on number of innovative and ambitious programmes across iiCON’s ten specialist research platforms.
www.infectioninnovation.com
|
|
|
|
|
|
